3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Completed
7
Recruiting
3
Terminated
2
Active not recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Sarcoma
3
Conditions
Hodgkin Disease
6
Sarcoma
3
Melanoma
2
Leiomyosarcoma
2
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Melanoma, Cutaneous Malignant
1
Lymphoma
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Hyperthermia
1
Advanced Melanoma
1
Interventions
Doxorubicin
15
pembrolizumab
12
Cyclophosphamide
9
Surgical Procedures, Operative
8
Gemcitabine
8
Blood Specimen Collection
8
Ifosfamide
7
Surveys and Questionnaires
6
Nivolumab
6
Trabectedin
5
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Drug Therapy
5
fludarabine
4
Temozolomide
4
Specimen Handling
4
Radiation Dose Hypofractionation
4
Biopsy
4
selinexor
3
pazopanib
3
liposomal doxorubicin
3
cabozantinib
3
atezolizumab
3
anlotinib
3
Radiation
3
Observation
3
Docetaxel
3
Dacarbazine
3
trastuzumab deruxtecan
2
toripalimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Sarcoma
×
Dacarbazine
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled
NCT06835049
2025-12-30
TNT-HYPE
Swiss Cancer Institute
Phase 2
Recruiting
24 enrolled
NCT03805022
2025-10-02
CIRSARC
Institut Bergonié
Phase 3
Recruiting
351 enrolled